Sartorius Stedim Biotech (CHIX:DIMP) Marketable Securities: €26 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
84 GF Score
Price €179.05
GF Value €208.05
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Marketable Securities?

Sartorius Stedim Biotech CHIX:DIMP 84 Marketable Securities is €26 Mil as of Mar. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €208.05 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sartorius Stedim Biotech's Marketable Securities for the quarter that ended in Mar. 2026 was €26 Mil.

Sartorius Stedim Biotech's annual Marketable Securities increased from Dec. 2023 (€10 Mil) to Dec. 2024 (€10 Mil) but then declined from Dec. 2024 (€10 Mil) to Dec. 2025 (€8 Mil).

Sartorius Stedim Biotech  (CHIX:DIMp) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sartorius Stedim Biotech Marketable Securities Related Terms

Sartorius Stedim Biotech Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Marketable Securities Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.70 0.00 9.50 9.90 8.10

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.40 45.80 39.50 8.10 26.20
CHIX:DIMP
84GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €26 Mil mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Marketable Securities of €26 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Marketable Securities too high?
Sartorius Stedim Biotech's current Marketable Securities is €26 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Marketable Securities compare to ISRG and BDX?
Sartorius Stedim Biotech's Marketable Securities of €26 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Marketable Securities is €26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €208.05, compared to a current price of €179.05 — trading 13.9% below its estimated fair value. The current Marketable Securities is €26 Mil. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Marketable Securities is €26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €179.05 is trading 13.9% below its estimated GF Value™ of €208.05. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

  • Marketable Securities: €26 Mil
  • GF Value™: €208.05 vs. price of €179.05 (13.9% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score

Get the complete analysis for CHIX:DIMP

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€179.05
Price
€208.05
GF Value